Nedocromil

Nedocromil

SCHEMBL316743

CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12.[NaH].[NaH]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.46
ABCB11 O95342 1/20 0.43
CYSLTR2 Q9NS75 2/20 0.41
CYSLTR1 Q9Y271 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TBXAS1 P24557 1/20 0.41
KMT2A Q03164 1/20 0.41
GPR35 Q9HC97 12/20 0.38
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
USP2 O75604 1/20 0.33
CSNK2A2 P19784 1/20 0.33
PTGS1 P23219 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
CSNK2A3 Q8NEV1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nedocromil SCHEMBL20481863 1.00 PDE5A (0.46) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL24943 1.00 PDE5A (0.46) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL4611 0.99 PDE5A (0.47) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL29406688 0.99 PDE5A (0.47) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL667050 0.98 PDE5A (0.46) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL2879046 0.98 PDE5A (0.46) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL28341341 0.98 PDE5A (0.46) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL17274068 0.96 PDE5A (0.44) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL22028284 0.94 PDE5A (0.44) PDE5AABCB11CYSLTR2CYSLTR1MEN1
Nedocromil SCHEMBL17473185 0.93 PDE5A (0.43) PDE5AABCB11CYSLTR2CYSLTR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034839-B2 Method of treating ocular allergy ALCON RESEARCH, LTD. (US) 2011-10-11 US claimed
WO-2011096941-A1 METHOD OF TREATING OCULAR ALLERGY ALCON RESEARCH, LTD. (US) 2011-08-11 WO claimed
US-20100160298-A1 METHOD OF TREATING OCULAR ALLERGY ALCON RESEARCH, LTD. (US) 2010-06-24 US claimed
US-7687539-B1 Method of treating ocular allergy ALCON RESEARCH, LTD. (US) 2010-03-30 US claimed
EP-1993741-B1 INLINE APPLICATION OF COATINGS COOK MEDICAL TECHNOLOGIES LLC (US) 2014-03-19 EP disclosed
US-8567410-B2 Magnet-field controlled active substance transfer for aerosol therapy ETHRIS GMBH (DE) 2013-10-29 US disclosed
US-8523937-B2 Controlled drug delivery using a zein layer modified with levulinic acid COOK MEDICAL TECHNOLOGIES LLC (US) 2013-09-03 US disclosed
US-8303648-B2 Artificial venous valve containing therapeutic agent COOK MEDICAL TECHNOLOGIES LLC (US) 2012-11-06 US disclosed
US-8092819-B2 Implantable medical device coated with a bioactive agent Cook Medical Technologies LLC. (US) 2012-01-10 US disclosed
US-8024851-B2 Method of producing a radially expandable prosthesis COOK MEDICAL TECHNOLOGIES LLC (US) 2011-09-27 US disclosed
US-7914841-B2 Inline application of coatings COOK MEDICAL TECHNOLOGIES LLC (US) 2011-03-29 US disclosed
EP-1981560-B1 ZEIN COATED MEDICAL DEVICE MED INST INC (US) 2010-09-08 EP disclosed
US-20070265699-A1 Artificial venous valve containing therapeutic agent MED INSTITUTE, INC. (US) 2007-11-15 US disclosed
US-20070207184-A1 Implantable medical device coated with a bioactive agent MED INSTITUTE, INC (US) 2007-09-06 US disclosed
US-20070207183-A1 Zein coated medical device MED INSTITUTE, INC. (US) 2007-09-06 US disclosed
US-20070196481-A1 Sustained-release tablet composition PHARMACIA CORPORATION 2007-08-23 US disclosed
US-20070196423-A1 Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent MED INSTITUTE, INC. (US) 2007-08-23 US disclosed
WO-2007089592-A2 IMPLANTABLE MEDICAL DEVICE COATED WITH BIOACTIVE AGENT MED INSTITUTE, INC. (US) 2007-08-09 WO disclosed
US-20070182055-A1 Inline application of coatings COOK INCORPORATED (US) 2007-08-09 US disclosed
US-20070043423-A1 Intraluminal device with a hollow structure MED INSTITUTE INC. (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070196481-A1 Sustained-release tablet composition SI, ABCB11, SLC2A9 PDE5A 1643/4885ABCB11 2/4885CYSLTR2 3526/4885
US-20100160298-A1 METHOD OF TREATING OCULAR ALLERGY HRH2, HRH1, HRH4 PDE5A 365/4885ABCB11 2647/4885CYSLTR2 17/4885
US-20070207183-A1 Zein coated medical device PCSK9, ZYX, ZFX PDE5A 3281/4885ABCB11 89/4885CYSLTR2 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.